Patents Represented by Attorney, Agent or Law Firm Shah Makujina
-
Patent number: 7030145Abstract: The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.Type: GrantFiled: March 12, 2004Date of Patent: April 18, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Richard A. Hartz, Argyrios G. Arvanitis
-
Patent number: 6818648Abstract: The present invention provides novel compounds, and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsey, irritable bowl syndrome, immune supression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R5, Q, Z, Y, V, X and X′ are as defined herein.Type: GrantFiled: March 17, 2003Date of Patent: November 16, 2004Assignee: Bristol-Myers Squibb PharmaInventors: Robert John Chorvat, Parthasarathi Rajagopalan
-
Patent number: 6727360Abstract: The present invention relates to processes for the production of &agr;-aryl-&bgr;-ketonitriles, which serve as synthetic intermediates in the preparation of a series of biologically important molecules such as corticotropin releasing factor (CRF) receptor antagonists.Type: GrantFiled: March 13, 2003Date of Patent: April 27, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Jiacheng Zhou, Lynette May Oh, Philip Ma
-
Patent number: 6686385Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.Type: GrantFiled: May 7, 2003Date of Patent: February 3, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, David Bertil Frennesson, Mikael Mahler, Kurt Zimmermann
-
Patent number: 6677450Abstract: The present invention relates to novel N12, N13-bridged sugar derivatives of indolylopyrrolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.Type: GrantFiled: September 27, 2001Date of Patent: January 13, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Francis Beaulieu, Carol Bachand, David B. Frennesson
-
Patent number: 6653290Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-I activity and are useful in inhibiting the proliferation of tumor cells.Type: GrantFiled: September 25, 2001Date of Patent: November 25, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Edward H. Ruediger, Neelakantan Balasubramanian, Mikael Mahler, Carol Bachand, Francis Beaulieu
-
Patent number: 6610727Abstract: The present invention concerns novel sugar derivatives of indolocarbazoles and pharmaceutical formulations thereof which exhibit topoisomerase-1 activity and are useful in inhibiting the proliferation of tumor cells.Type: GrantFiled: September 27, 2001Date of Patent: August 26, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Mark G. Saulnier, Edward H. Ruediger, Neelakantan Balasubramanian, David Bertil Frennesson, Mikael Mahler, Kurt Zimmermann
-
Patent number: 6589958Abstract: The present invention describes novel isoxazolo[1,5-a]pyrimidines of formula: wherein R is an aromatic or heteroaromatic ring, or pharmaceutically acceptable salt form thereof, which are useful as CRF antagonists.Type: GrantFiled: March 27, 2002Date of Patent: July 8, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventor: William Eric Frietze
-
Patent number: 6589952Abstract: Provided herein are novel imidazo[1,2-a]pyrazines of Formula I: wherein: X is CHR5, NR5, O, S, S(O)n or a single bond, wherein n is equal to 0, 1 or 2; D is aryl or heteroaryl attached through an unsaturated carbon atom and wherein said aryl or heteroaryl is optionally substituted at any available position with from 1-5 of A1, A2, A3, A4 and A5; R2 is C1-4 alkyl or C3-8 cycloalkyl, each of which is optionally substituted with from 1-3 hydroxy, halogen or C1-4 alkoxy, or wherein when X is a bond, R2 is optionally also CN, CF3, C2F5, C1-4 alkyl or C3-8 cycloalkyl, each of which C1-4 alkyl or C3-8 cycloalkyl is optionally substituted with from 1-3 hydroxy, halogen and C1-4 alkoxy; as well as compositions containing the same, useful in the treatment of, for example, neurological and psychological disorders characterized by corticotropin releasing factor (CRF) overexpression.Type: GrantFiled: July 13, 2001Date of Patent: July 8, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Rajagopal Bakthavatchalam, Richard G. Wilde, Paul J. Gilligan
-
Patent number: 6579876Abstract: The present invention describes novel compounds of formula (Ib): wherein D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as corticotropin releasing factor antagonists.Type: GrantFiled: February 11, 2002Date of Patent: June 17, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
-
Patent number: 6187789Abstract: Ultrashort acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein: X is a halogen; h is from 1 to 2; Y is hydrogen or methoxy; Z1 and Z2 are methyl; W1 and W2 are carbon; and A is a pharmaceutically acceptable anion.Type: GrantFiled: January 19, 2000Date of Patent: February 13, 2001Assignees: Glaxo Wellcome Inc., Cornell Research Foundation Inc.Inventors: Eric Cleveland Bigham, Grady Evan Boswell, John Joseph Savarese, Roy Archibald Swaringen, Jr., Sanjay Shashikant Patel, Eric Eugene Boros, Robert Anthony Mook, Jr., Vincente Samano
-
Patent number: 6177445Abstract: Ultra short acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein q and t are independently from 0 to 4; X1 and X2 are independently halogen; ha and hb are independenity from 0 to 2; Z1 and Z2 are indepentdently hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl with the proviso that Z1 and Z2 are not both hydrogen; Y1, Y2, and Y3 and Y4 are independently hydrogen, halogen or C1-3 alkoxy; m and p are independently 1 to 6; n and r are independently 0 to 4; with the proviso the if ha and hb are both 0, then r is 0 and n is 0 to 2; R1 to R14 are independently hydrogen, halogen, C1-3 alkoxy, or R2 and R3 together with the carbon atoms to which they are bonded, R5 and R6 together with the carbon atoms to which they are bonded, R9 and R10 together with the carbon atoms to which they are bonded, R12 and R13 together with the carbon atoms to which they are bonded, mayType: GrantFiled: December 22, 1999Date of Patent: January 23, 2001Assignees: Glaxo Wellcome Inc., Cornell Research Foundation Inc.Inventors: Eric Cleveland Bigham, Grady Evan Boswell, John Joseph Savarese, Roy Archibald Swaringen, Jr., Sanjay Shashikant Patel, Eric Eugene Boros, Robert Anthony Mook, Jr., Vincente Samano